therapeutics < therapies < therapy

Facettes :

List of bibliographic references indexed by therapies

Number of relevant bibliographic references: 23.
[0-20] [0 - 20][0 - 23][20-22][20-40]

Ident.	Authors (with country if any)	Title
000056 (2017)	Marc Morissette [Canada] ; Thérèse Di Paolo [Canada]	Non-human primate models of PD to test novel therapies.
000281 (2016)	Shichun Peng [États-Unis] ; Yilong Ma [États-Unis] ; Joseph Flores [Canada] ; Michael Cornfeldt [États-Unis] ; Branka Mitrovic [États-Unis] ; David Eidelberg [États-Unis] ; Doris J. Doudet [Canada]	Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation
000449 (2016)	Michael D. Staudt [Canada] ; Andrea R. Di Sebastiano ; Hu Xu ; Mandar Jog ; Susanne Schmid ; Paula Foster ; Matthew O. Hebb	Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review.
000628 (2015)	Nafiseh Nafissi ; Marianna Foldvari	Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools
000861 (2014)	Ido Strauss [Canada] ; Suneil K. Kalia ; Andres M. Lozano	Where are we with surgical therapies for Parkinson's disease?
000883 (2014)	Daniela Kuzdas-Wood [Autriche] ; Nadia Stefanova [Autriche] ; Kurt A. Jellinger [Autriche] ; Klaus Seppi [Autriche] ; Michael G. Schlossmacher [Canada] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]	Towards translational therapies for multiple system atrophy
000901 (2014)	Francesca Cicchetti [Canada] ; Roger A. Barker [Royaume-Uni]	The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?
000D01 (2013)	Amaal Aldakheel ; Lorraine V. Kalia ; Anthony E. Lang	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
001355 (2012)	Hossein Ardehali [États-Unis] ; Hani N. Sabbah [États-Unis] ; Michael A. Burke [États-Unis] ; Satyam Sarma [États-Unis] ; Peter P. Liu [Canada] ; John G. F. Cleland [Royaume-Uni] ; Aldo Maggioni [Italie] ; Gregg C. Fonarow [États-Unis] ; E. Dale Abel [États-Unis] ; Umberto Campia [États-Unis] ; Mihai Gheorghiade [États-Unis]	Targeting myocardial substrate metabolism in heart failure: potential for new therapies
001404 (2012)	Maria C. Rodriguez-Oroz [Espagne] ; Elena Moro [Canada] ; Paul Krack [France]	Long‐term outcomes of surgical therapies for Parkinson's disease
001510 (2012)	Maria C. Rodriguez-Oroz [Espagne] ; Elena Moro [Canada] ; Paul Krack [France]	Long-Term Outcomes of Surgical Therapies for Parkinson's Disease
001687 (2011)	Penny A. Macdonald [Canada] ; Oury Monchi [Canada]	Differential Effects of Dopaminergic Therapies on Dorsal and Ventral Striatum in Parkinson's Disease: Implications for Cognitive Function
001723 (2011)	Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. Brotchie	Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
001980 (2010)	Raúl De La Fuente-Fernández [Canada] ; Michael Schulzer ; Edwin Mak ; Vesna Sossi	Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
002719 (2006)	O. Suchowersky [Canada] ; G. Gronseth ; J. Perlmutter ; S. Reich ; T. Zesiewicz ; W J Weiner	Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
002729 (2006)	Joseph S. Neimat [Canada] ; Clement Hamani ; Andres M. Lozano	Neural stimulation for Parkinson's disease: current therapies and future directions.
002818 (2006)	Joseph S. Neimat [Canada] ; Parag G. Patil [Canada] ; Andres M. Lozano [Canada]	Novel Surgical Therapies for Tourette Syndrome
002910 (2006)	O. Suchowersky [Canada] ; G. Gronseth [États-Unis] ; J. Perlmutter [États-Unis] ; S. Reich [États-Unis] ; T. Zesiewicz [États-Unis] ; W. J. Weiner [États-Unis]	Practice Parameter:Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology
002C49 (2004)	Jacqueline Low [Canada]	Managing Safety and Risk: The Experiences of People with Parkinson’s Disease who Use Alternative and Complementary Therapies
002D27 (2004)	Mark D. Berry [Canada]	Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders
003283 (2001)	C. Warren Olanow [États-Unis] ; Mitchell F. Brin [États-Unis]	Surgical therapies for Parkinson's disease: A physician's perspective

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "therapies" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "therapies" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    therapies
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022